Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical is a pioneering biotech company focused on revolutionizing inflammatory care through its proprietary PAIR (Pleiotropic Anti-Inflammatory Remedies) technology. Since 2014, it has been developing safe, effective solutions that address inflammation at its biological origin, aiming to extend healthspan and transform healthcare by targeting chronic inflammation and metabolic disorders. The company collaborates with global partners, holds over 60 patents, and is advancing a broad pipeline of therapeutics for conditions such as respiratory infections, opioid withdrawal, obesity, and aging-related inflammation.
Industries
Nr. of Employees
small (1-50)
Sen-Jam Pharmaceutical
Products
SJP-002C (upper-respiratory infection oral therapy)
An oral dual-mechanism small-molecule therapy developed to modulate early inflammatory responses in upper-respiratory infections; completed Phase 2 studies reporting safety and early symptom reduction.
SJP-001 (metabolic recovery / hangover prevention, oral)
Oral therapy combining an NSAID-class agent with a mast-cell modulator to reduce alcohol- and diet-induced inflammatory responses; received ethics approval in Australia and progressing in clinical trials.
SJP-005 (opioid withdrawal relief, oral)
Non-opioid oral therapeutic intended to modulate inflammatory rebound during opioid withdrawal to reduce withdrawal symptoms and support recovery; reported preclinical and pilot human data and attracted NIDA interest/support.
SJP-100 (critical-care injectable rescue)
Injectable formulation engineered for IV administration in hospital critical-care settings to modulate upstream inflammatory cascades implicated in sepsis, ARDS and multi-organ dysfunction.
Preclinical and early-stage pipeline (additional oral and injectable programs)
A set of additional indication-specific programs (arthritis, vaccination side-effect mitigation, opioid dependence/tolerance, low-grade chronic inflammation/anti-aging) using the same dual-mechanism platform across oral and injectable formats.
SJP-002C (upper-respiratory infection oral therapy)
An oral dual-mechanism small-molecule therapy developed to modulate early inflammatory responses in upper-respiratory infections; completed Phase 2 studies reporting safety and early symptom reduction.
SJP-001 (metabolic recovery / hangover prevention, oral)
Oral therapy combining an NSAID-class agent with a mast-cell modulator to reduce alcohol- and diet-induced inflammatory responses; received ethics approval in Australia and progressing in clinical trials.
SJP-005 (opioid withdrawal relief, oral)
Non-opioid oral therapeutic intended to modulate inflammatory rebound during opioid withdrawal to reduce withdrawal symptoms and support recovery; reported preclinical and pilot human data and attracted NIDA interest/support.
SJP-100 (critical-care injectable rescue)
Injectable formulation engineered for IV administration in hospital critical-care settings to modulate upstream inflammatory cascades implicated in sepsis, ARDS and multi-organ dysfunction.
Preclinical and early-stage pipeline (additional oral and injectable programs)
A set of additional indication-specific programs (arthritis, vaccination side-effect mitigation, opioid dependence/tolerance, low-grade chronic inflammation/anti-aging) using the same dual-mechanism platform across oral and injectable formats.
Services
Co-development and licensing
Partnerships for co-development, regional or global licensing, milestone-based deals and joint ventures to commercialize pipeline assets.
Clinical trial management via CRO partnerships
Sponsor-side management and execution of early-phase clinical trials using external CROs and clinical research networks.
Manufacturing and CMC collaboration
Collaboration with contract manufacturing and CMC partners to provide scale-ready production, stability testing and submission batches for regulatory filings.
Co-development and licensing
Partnerships for co-development, regional or global licensing, milestone-based deals and joint ventures to commercialize pipeline assets.
Clinical trial management via CRO partnerships
Sponsor-side management and execution of early-phase clinical trials using external CROs and clinical research networks.
Manufacturing and CMC collaboration
Collaboration with contract manufacturing and CMC partners to provide scale-ready production, stability testing and submission batches for regulatory filings.
Expertise Areas
- Inflammation-focused drug development
- Combination small-molecule therapeutics
- Clinical trial management (Phase 1–2)
- Regulatory strategy for 505(b)(2) and OTC pathways
Key Technologies
- Mast cell modulation
- COX1/COX2 inhibition
- Small-molecule combination therapies
- Oral formulation development